Topics

FDA Approves First-Line Pembrolizumab for Head/Neck Squamous Cell Carcinoma

20:00 EDT 11 Jun 2019 | Cancer Networks

The FDA approved pembrolizumab for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma

Original Article: FDA Approves First-Line Pembrolizumab for Head/Neck Squamous Cell Carcinoma

NEXT ARTICLE

More From BioPortfolio on "FDA Approves First-Line Pembrolizumab for Head/Neck Squamous Cell Carcinoma"

Quick Search

Relevant Topic

Skin cancers
There are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma and malignant melanoma. Basal cell carcinoma Basal cell carcinoma, or BCC, is a cancer of the basal cells at the bottom of the epidermis. It’s very common ...